KLRK1 and colorectal cancer: Studies concerning the use of NKG2D-chimeric receptor engineered-NK cells, tested for the treatment of leukemia and solid tumors such as colorectal cancer, have shown promising results [(65, 66), ClinicalTrial.gov and Supplementary Table S1].